X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Divis Laboratories Fact Sheet, Divis Laboratories Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Divis Laboratories Fact Sheet   (DIVI)

Here is the latest financial fact sheet of Divis Laboratories. For more details, see the Divis Laboratories quarterly results and Divis Laboratories share price and chart. For a sector overview, read our pharmaceuticals sector report.

DIVIS LABORATORIES Price History

Price Rs 1,008.5
Mkt Cap Rs m 267,724
Vol '000 43.3
P/E X 28.8
P/CF X 22.6
EPS (TTM) Rs 35.0
% ch % -0.5
No. of shares m 265.47
% ch week % -4.0
% ch 1-mth % -6.5
% ch 12-mth % 32.3
52 week H/L Rs 1,141.8/533.1
(As on Feb 21, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

DIVIS LABORATORIES Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
DIVIS LABORATORIES EQUITY SHARE DATA
High Rs1,2331,4591,8812,4841,222 
Low Rs7529051,217918784 
Sales per share (Unadj.) Rs161.6190.8234.7142.3153.1 
Earnings per share (Unadj.) Rs45.458.364.242.439.9 
Diluted earnings per shareRs22.729.132.142.439.9 
Cash flow per share (Unadj.) Rs51.265.274.446.944.6 
Dividends per share (Unadj.) Rs15.0020.0020.0010.0010.00 
Adj. dividends per shareRs7.5010.0010.0010.0010.00 
Dividend yield (eoy) %1.51.71.30.61.0 
Book value per share (Unadj.) Rs188.4223.3288.0161.7201.8 
Adj. book value per shareRs94.2111.6144.0161.7201.8 
Shares outstanding (eoy) m132.73132.73132.73265.47265.47 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x6.16.26.612.06.6 
Avg P/E ratio x21.920.324.140.125.1 
P/CF ratio (eoy) x19.418.120.836.322.5 
Price / Book Value ratio x5.35.35.410.55.0 
Dividend payout %33.134.331.223.625.0 
Avg Mkt Cap Rs m131,735156,887205,599451,525266,266 
No. of employees `000NANA8.79.59.7 
Total wages/salary Rs m1,9772,3252,9043,6124,687 
Avg. sales/employee Rs ThNMNM3,571.83,983.14,175.0 
Avg. wages/employee Rs ThNMNM333.0381.0481.5 
Avg. net profit/employee Rs ThNMNM976.41,187.41,089.3 
DIVIS LABORATORIES INCOME DATA
Net Sales Rs m21,44825,32131,14937,76440,643 
Other income Rs m448706447974749 
Total revenues Rs m21,89726,02731,59638,73841,392 
Gross profit Rs m8,15210,14511,65214,17414,460 
Depreciation Rs m7709211,3601,1821,233 
Interest Rs m1821193823 
Profit before tax Rs m7,8129,90910,72113,92813,953 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m1,7922,1762,2062,6713,349 
Profit after tax Rs m6,0207,7338,51511,25810,604 
Gross profit margin %38.040.137.437.535.6 
Effective tax rate %22.922.020.619.224.0 
Net profit margin %28.130.527.329.826.1 
DIVIS LABORATORIES BALANCE SHEET DATA
Current assets Rs m18,64122,56427,72430,27040,105 
Current liabilities Rs m5,5456,2744,5605,1956,595 
Net working cap to sales %61.164.374.466.482.5 
Current ratio x3.43.66.15.86.1 
Inventory Days Days142134136117119 
Debtors Days Days87104878581 
Net fixed assets Rs m12,12113,66315,23116,99819,995 
Share capital Rs m266266266531531 
"Free" reserves Rs m24,73529,36337,95842,40253,043 
Net worth Rs m25,00629,63438,22342,93353,574 
Long term debt Rs m21161150 
Total assets Rs m31,38837,10543,82949,02161,585 
Interest coverage x439.9482.0577.4369.5618.4 
Debt to equity ratio x00000 
Sales to assets ratio x0.70.70.70.80.7 
Return on assets %19.220.919.523.017.3 
Return on equity %24.126.122.326.219.8 
Return on capital %31.333.528.132.526.1 
Exports to sales %86.789.284.385.30 
Imports to sales %21.820.023.922.925.2 
Exports (fob) Rs m18,60222,57526,24432,1980 
Imports (cif) Rs m4,6815,0697,4428,65410,259 
Fx inflow Rs m18,78922,61726,31732,27035,384 
Fx outflow Rs m4,7965,1837,5888,77510,399 
Net fx Rs m13,99317,43418,72923,49624,985 
DIVIS LABORATORIES CASH FLOW
From Operations Rs m 4,800 5,568 8,263 10,379 11,493 
From Investments Rs m -2,545 -3,052 -5,208 -4,064 -11,372 
From Financial Activity Rs m -2,308 -2,485 -3,030 -6,311 -93 
Net Cashflow Rs m -53 31 25 3 28 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 52.0%
Foreign collaborators 0.0%
Indian inst/Mut Fund 11.8%
FIIs 19.0%
ADR/GDR 0.0%
Free float 17.2%
Shareholders 31,796
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF 7-1-77/E/1/303, Divi Towers, Dharam Karan Road, Ameerpet, Hyderabad-16
E-MAIL cs@divislaboratories.com WEB www.divislaboratories.com
TELEPHONE (040) 2378 6300 FAX (040) 2378 6460
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR P. V. R. K. Nageswara Rao & Co.
CHM: Murali K. Divi (MD) COMP SEC: P. V. Lakshmi Rajani YEAR OF INC: 1990 BSE CODE: 532488 FV (Rs): 2 DIV YIELD (%): 1.0

More Pharmaceuticals Company Fact Sheets:   AMAR REMEDIES  ALEMBIC LTD  SUN PHARMA  CIPLA  AJANTA PHARMA  

Compare DIVIS LABORATORIES With:   AMAR REMEDIES  ALEMBIC LTD  SUN PHARMA  CIPLA  AJANTA PHARMA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - ACTAVIS COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS